{ "items": [ "\n\n
\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n22 February 2023
\n \n \n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n17 February 2023
\n \n \n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n4 January 2023
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Hand\n \n \n \n \n Kennedy\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n15 November 2022
\n \n \n \nResearchers at the Kennedy Institute of Rheumatology and Oxford Population Health\u2019s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren\u2019s disease.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n12 October 2022
\n \n \n \nOCTRU and the Experimental Medicine and Rheumatology trial group are delighted to announce that their latest study IMPROVE is now open and recruiting. The IMPROVE study is investigating if the immune response to COVID-19 vaccination can be improved in those with Chronic Lymphocytic Leukaemia (CLL) by pausing BTKi treatment for 3 weeks around the time of vaccination. The study is led by Dr Helen Parry at the University of Birmingham and funded by the NIHR and will recruit around 120 patients from 8 NHS Trusts in the UK. To coincide with the autumn COVID-19 vaccination programme all those involved in the study set have been working at great pace to reach this critical milestone and we look forward to supporting sites during the busy recruitment period.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n12 October 2022
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Awards\n \n \n \n \n OCTRU\n \n \n \n \n Orthopaedics and trauma\n \n \n \n \n SITU\n \n \n\n \n\n\n
\n \n\n \n4 October 2022
\n \n \n \nCongratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n28 September 2022
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Knee\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n \n \n SITU\n \n \n \n \n Trials\n \n \n\n \n\n\n
\n \n\n \n23 August 2022
\n \n \n \nNew research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n23 August 2022
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Funding\n \n \n \n \n Hip\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n \n \n Orthopaedics and trauma\n \n \n \n \n Trauma\n \n \n\n \n\n\n
\n \n\n \n27 July 2022
\n \n \n \nResearchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.
\n \n\n \n \n\n \n\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n \n \n Trauma\n \n \n \n \n Trials\n \n \n\n \n\n\n
\n \n\n \n6 July 2022
\n \n \n \nNew research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n \n \n Trials\n \n \n\n \n\n\n
\n \n\n \n29 June 2022
\n \n \n \nThe Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n \n \n RRIO\n \n \n \n \n SITU\n \n \n \n \n Trials\n \n \n\n \n\n\n
\n \n\n \n20 May 2022
\n \n \n \nTo mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.
\n \n\n \n \n\n \n\n \n \n \n \n Hand\n \n \n \n \n Kennedy\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n \n \n Trials\n \n \n\n \n\n\n
\n \n\n \n30 April 2022
\n \n \n \nInjection of the anti-TNF drug adalimumab into Dupuytren\u2019s disease nodules is effective in reducing nodule hardness and nodule size.
\n \n\n \n \n\n \n\n \n \n \n \n Knee\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n \n \n SITU\n \n \n\n \n\n\n
\n \n\n \n6 April 2022
\n \n \n \nA new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n4 April 2022
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Hip\n \n \n \n \n Main\n \n \n \n \n OCTRU\n \n \n \n \n Orthopaedics and trauma\n \n \n \n \n Trials\n \n \n\n \n\n\n
\n \n\n \n10 February 2022
\n \n \n \nThe White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n2 February 2022
\n \n \n \nFUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.
\n \n\n \n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n31 January 2022
\n \n \n \n\n \n \n